Why Automated Safety Report Notification Makes Sense

To reduce the risk for both patients and clinical trial sponsors, pharmaceutical companies must send written safety notifications to investigators and other stakeholders within a tightly defined time frame after first becoming aware of a Suspected Unexpected Serious Adverse Reaction (SUSAR). Yet a manual approach is costly and labor-intensive, with no assurances for full compliance.



Challenges of a Manual Process

- Distributing safety reports within regulated timeframes
- Costly and labor-intensive manual processes & distribution methods
- Complying with country specific requirements
- Tracking acknowledgement receipts
- Providing documentation for the Trial Master File





LEARN MORE

Webinar: SUSAR Reporting- Taking the Pain Out of Regulatory Compliance